Konruns(SH:603590) Ge Long Hui·2025-09-29 11:26Core Viewpoint - Kangchen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug classified as a Class 1 new drug [1] - The drug targets multiple pathways by inhibiting VEGFR2 and AXL to achieve anti-tumor activity [1] - KC1036 exhibits strong vascular targeting of VEGFR, inhibiting tumor cell growth, and improving host anti-tumor immune response by suppressing AXL, thus preventing immune evasion by tumors [1] Group 2: Clinical Research - Clinical trials for KC1036 are set to commence shortly, with over 300 subjects already enrolled in ongoing clinical studies for multiple indications [1]